Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 248

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 248
---
LEARMIND MEDICINE INC. Index of Financial Statements As of October 31, 2024

|                                                                      |     | Page |
| Reports of Independent Registered Public Accounting Firms            |     | F-3  |
| (Firm Name: Brightman Almagor Zohar & Co / PCAOB ID No. 1197)        |     | F-3  |
| Consolidated Statements of Financial Position                        |     | F-4  |
| Consolidated Statements of Operations and Comprehensive Loss         |     | F-5  |
| Consolidated Statements of Changes in Shareholders’ Equity (Deficit) |     | F-6  |
| Consolidated Statements of Cash Flows                                |     | F-7  |
| Notes to the Consolidated Financial Statements                       |     | F-8  |

F-2 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the shareholders and the Board of Directors of Clearmind Medicine Inc. Opinion on the Financial Statements We have audited the accompanying consolidated statements of financial position of Clearmind Medicine Inc. and its subsidiaries (the “Company”) as of October 31, 2024, and 2023, the related consolidated statements of operations and comprehensive loss, changes in shareholders’ equity (deficit) and cash flows for each of the three years in the period ended October 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of October 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended October 31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1b to the financial statements, the Company’s accumulated losses and the additional funds needed to maintain its operations raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1b. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public